merit medical systems inc. - MMSI

MMSI

Close Chg Chg %
88.56 -0.42 -0.47%

Closed Market

88.14

-0.42 (0.47%)

Volume: 343.22K

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: merit medical systems inc. - MMSI

MMSI Key Data

Open

$88.55

Day Range

87.79 - 88.87

52 Week Range

78.12 - 111.45

Market Cap

$5.23B

Shares Outstanding

59.29M

Public Float

57.85M

Beta

0.62

Rev. Per Employee

N/A

P/E Ratio

45.33

EPS

$2.01

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

580.88K

 

MMSI Performance

1 Week
 
0.86%
 
1 Month
 
5.65%
 
3 Months
 
4.67%
 
1 Year
 
-8.87%
 
5 Years
 
58.78%
 

MMSI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About merit medical systems inc. - MMSI

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

MMSI At a Glance

Merit Medical Systems, Inc.
1600 West Merit Parkway
South Jordan, Utah 84095
Phone 1-801-253-1600 Revenue 1.35B
Industry Medical Specialties Net Income 120.36M
Sector Health Technology 2024 Sales Growth 8.066%
Fiscal Year-end 12 / 2025 Employees 7,400
View SEC Filings

MMSI Valuation

P/E Current 45.327
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 47.706
Price to Sales Ratio 4.239
Price to Book Ratio 4.119
Price to Cash Flow Ratio 26.00
Enterprise Value to EBITDA 22.706
Enterprise Value to Sales 4.546
Total Debt to Enterprise Value 0.129

MMSI Efficiency

Revenue/Employee 183,023.514
Income Per Employee 16,264.459
Receivables Turnover 6.475
Total Asset Turnover 0.571

MMSI Liquidity

Current Ratio 4.269
Quick Ratio 2.854
Cash Ratio 1.751

MMSI Profitability

Gross Margin 47.295
Operating Margin 11.552
Pretax Margin 11.075
Net Margin 8.887
Return on Assets 5.074
Return on Equity 9.325
Return on Total Capital 5.536
Return on Invested Capital 5.671

MMSI Capital Structure

Total Debt to Total Equity 57.611
Total Debt to Total Capital 36.553
Total Debt to Total Assets 32.856
Long-Term Debt to Equity 56.862
Long-Term Debt to Total Capital 36.078
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Merit Medical Systems Inc. - MMSI

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.08B 1.15B 1.25B 1.35B
Sales Growth
+12.09% +6.21% +9.23% +8.07%
Cost of Goods Sold (COGS) incl D&A
640.03M 678.85M 731.05M 713.83M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
95.78M 92.20M 101.29M 114.73M
Depreciation
46.18M 43.80M 45.19M 49.13M
Amortization of Intangibles
49.60M 48.40M 56.10M 65.60M
COGS Growth
+3.23% +6.06% +7.69% -2.36%
Gross Income
440.31M 468.55M 522.23M 640.55M
Gross Income Growth
+28.06% +6.41% +11.46% +22.66%
Gross Profit Margin
+40.76% +40.84% +41.67% +47.29%
2021 2022 2023 2024 5-year trend
SG&A Expense
357.41M 369.63M 400.30M 484.10M
Research & Development
71.25M 75.51M 82.73M 87.47M
Other SG&A
286.17M 294.13M 317.58M 396.63M
SGA Growth
+20.47% +3.42% +8.30% +20.93%
Other Operating Expense
- - - -
-
Unusual Expense
19.08M 12.58M 1.52M 1.58M
EBIT after Unusual Expense
63.82M 86.34M 120.41M 154.87M
Non Operating Income/Expense
(6.15M) 2.62M 9.74M 28.00M
Non-Operating Interest Income
769.00K 439.00K 2.46M 26.23M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.75M 6.33M 18.06M 32.88M
Interest Expense Growth
-58.87% +68.63% +185.46% +82.02%
Gross Interest Expense
3.75M 6.33M 18.06M 32.88M
Interest Capitalized
- - - -
-
Pretax Income
53.92M 82.63M 112.09M 149.99M
Pretax Income Growth
+507.51% +53.25% +35.65% +33.82%
Pretax Margin
+4.99% +7.20% +8.94% +11.07%
Income Tax
5.46M 8.11M 17.68M 29.64M
Income Tax - Current - Domestic
1.61M 12.75M 19.46M 31.35M
Income Tax - Current - Foreign
8.48M 10.29M 10.86M 13.16M
Income Tax - Deferred - Domestic
(2.31M) (14.05M) (12.73M) (14.03M)
Income Tax - Deferred - Foreign
(2.32M) (871.00K) 86.00K (843.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
48.45M 74.52M 94.41M 120.36M
Minority Interest Expense
- - - -
-
Net Income
48.45M 74.52M 94.41M 120.36M
Net Income Growth
+592.27% +53.79% +26.70% +27.48%
Net Margin Growth
+4.49% +6.49% +7.53% +8.89%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
48.45M 74.52M 94.41M 120.36M
Preferred Dividends
- - - -
-
Net Income Available to Common
48.45M 74.52M 94.41M 120.36M
EPS (Basic)
0.863 1.3118 1.6393 2.0673
EPS (Basic) Growth
+585.92% +52.00% +24.97% +26.11%
Basic Shares Outstanding
56.15M 56.81M 57.59M 58.22M
EPS (Diluted)
0.8448 1.2921 1.6178 2.0274
EPS (Diluted) Growth
+575.68% +52.95% +25.21% +25.32%
Diluted Shares Outstanding
57.36M 57.67M 58.36M 59.37M
EBITDA
178.68M 191.12M 223.22M 271.18M
EBITDA Growth
+16.05% +6.96% +16.80% +21.49%
EBITDA Margin
+16.54% +16.66% +17.81% +20.02%

Snapshot

Average Recommendation BUY Average Target Price 103.00
Number of Ratings 11 Current Quarters Estimate 0.888
FY Report Date 03 / 2026 Current Year's Estimate 4.011
Last Quarter’s Earnings 0.951 Median PE on CY Estimate N/A
Year Ago Earnings 3.734 Next Fiscal Year Estimate 4.379
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 9 8
Mean Estimate 0.89 1.05 4.01 4.38
High Estimates 0.95 1.15 4.20 4.56
Low Estimate 0.81 1.00 3.87 4.18
Coefficient of Variance 4.78 5.17 2.46 3.44

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 8
OVERWEIGHT 3 3 2
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Merit Medical Systems Inc. - MMSI

Date Name Shares Transaction Value
Nov 21, 2025 Fred P. Lampropoulos Executive Chairman; Director 1,074,955 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.83 per share 91,188,432.65
Aug 13, 2025 Lynne N. Ward Director 15,242 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $34.46 per share 525,239.32
Aug 13, 2025 Lynne N. Ward Director 12,809 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.89 per share 1,087,356.01
Aug 13, 2025 Lynne N. Ward Director 3,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2025 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY 34,245 Bona fide gift 0.00
Mar 7, 2025 Fred P. Lampropoulos President and CEO; Director 1,106,028 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.05 per share 115,082,213.40
Mar 7, 2025 Fred P. Lampropoulos President and CEO; Director 10,324 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.75 per share 1,071,115.00
Mar 7, 2025 Fred P. Lampropoulos President and CEO; Director 7,734 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.75 per share 802,402.50
Mar 7, 2025 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY 68,945 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $55.73 per share 3,842,304.85
Mar 7, 2025 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY 38,945 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.9 per share 4,007,440.50
Mar 7, 2025 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Raul Parra CFO AND TREASURER 29,562 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $37.71 per share 1,114,783.02
Mar 7, 2025 Raul Parra CFO AND TREASURER 24,201 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.58 per share 2,506,739.58
Mar 7, 2025 Raul Parra CFO AND TREASURER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Michel J. Voigt CHIEF HUMAN RESOURCES OFFICER 21,779 Bona fide gift 0.00

Merit Medical Systems Inc. in the News